DDInter1635 DDInter1435
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Salmeterol {u} may lead to a major life threatening interaction when taken with {v} Labetalol
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salmeterol {u} (Compound) resembles {v} (Compound) Hexoprenaline
Salmeterol {u} (Compound) treats {v} (Disease) asthma
Salmeterol {u} (Compound) binds {v} (Gene) ADRB2
Salmeterol {u} (Compound) upregulates {v} (Gene) EDEM1
Salmeterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Salmeterol {u} (Compound) downregulates {v} (Gene) CDC20
Salmeterol {u} (Compound) causes {v} (Side Effect) Chronic obstructive pulmonary disease
Salmeterol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hydrocortisone
Salmeterol may lead to a major life threatening interaction when taken with Labetalol
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Salmeterol (Compound) resembles Hexoprenaline (Compound)
Salmeterol (Compound) treats asthma (Disease)
Salmeterol (Compound) binds ADRB2 (Gene)
Salmeterol (Compound) upregulates EDEM1 (Gene)
Salmeterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Salmeterol (Compound) downregulates CDC20 (Gene)
Salmeterol (Compound) causes Chronic obstructive pulmonary disease (Side Effect)
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone